In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11

Jeanette A M Maier, Domenico Delia, Philip E. Thorpe, Giampietro Gasparini

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Angiogenesis plays a key role in tumor growth, progression and metastasis. The modulation of angiogenesis represents a potentially useful target for novel forms of anticancer therapy. Two such modulators are AGM-1470 (TNP-470, angioinhibin), which is a synthetic analog of the antibiotic fumagallin, and the monoclonal antibody TEC-11 to endoglin. We investigated the mechanisms of action of these modulators on human microvascular and macrovascular endothelial cells and on the transformed endothelial cell line ECV-304 in vitro. The administration of AGM-1470 or TEC-11 resulted in a significant inhibition of cell proliferation in all cell types used; this effect was reversible upon removal of these compounds from the culture medium. Furthermore, biochemical and morphological analyses showed that neither AGM-1470 or TEC-11 induce apoptosis. Both AGM-1470 and TEC-11 inhibited the production of urokinase-type plasminogen activator (u-PA), an enzyme involved in the early steps of neovascularization. Finally, the incubation of endothelial cells with both AGM-1470 and TEC-11 did not produce an additive effect on growth cell inhibition, apoptosis or u-PA production. Since both AGM-1470 and TEC-11 inhibit crucial events such as endothelial cell growth and protease production, our results provide a basis for their therapeutic use as angiostatic molecules in cancer.

Original languageEnglish
Pages (from-to)238-244
Number of pages7
JournalAnti-Cancer Drugs
Volume8
Issue number3
DOIs
Publication statusPublished - 1997

Fingerprint

Anti-Idiotypic Antibodies
Endothelial Cells
Growth
Pharmaceutical Preparations
Urokinase-Type Plasminogen Activator
Enzyme Activators
Apoptosis
Transformed Cell Line
Therapeutic Uses
In Vitro Techniques
O-(chloroacetylcarbamoyl)fumagillol
Endoglin
Culture Media
Neoplasms
Peptide Hydrolases
Monoclonal Antibodies
Cell Proliferation
Neoplasm Metastasis
Anti-Bacterial Agents

Keywords

  • angiogenesis
  • angiogenesis inhibitors
  • human endothelial cells

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research
  • Oncology

Cite this

In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11. / Maier, Jeanette A M; Delia, Domenico; Thorpe, Philip E.; Gasparini, Giampietro.

In: Anti-Cancer Drugs, Vol. 8, No. 3, 1997, p. 238-244.

Research output: Contribution to journalArticle

Maier, Jeanette A M ; Delia, Domenico ; Thorpe, Philip E. ; Gasparini, Giampietro. / In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11. In: Anti-Cancer Drugs. 1997 ; Vol. 8, No. 3. pp. 238-244.
@article{61c1bfd775ea4ccf965d030816a5f7f6,
title = "In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11",
abstract = "Angiogenesis plays a key role in tumor growth, progression and metastasis. The modulation of angiogenesis represents a potentially useful target for novel forms of anticancer therapy. Two such modulators are AGM-1470 (TNP-470, angioinhibin), which is a synthetic analog of the antibiotic fumagallin, and the monoclonal antibody TEC-11 to endoglin. We investigated the mechanisms of action of these modulators on human microvascular and macrovascular endothelial cells and on the transformed endothelial cell line ECV-304 in vitro. The administration of AGM-1470 or TEC-11 resulted in a significant inhibition of cell proliferation in all cell types used; this effect was reversible upon removal of these compounds from the culture medium. Furthermore, biochemical and morphological analyses showed that neither AGM-1470 or TEC-11 induce apoptosis. Both AGM-1470 and TEC-11 inhibited the production of urokinase-type plasminogen activator (u-PA), an enzyme involved in the early steps of neovascularization. Finally, the incubation of endothelial cells with both AGM-1470 and TEC-11 did not produce an additive effect on growth cell inhibition, apoptosis or u-PA production. Since both AGM-1470 and TEC-11 inhibit crucial events such as endothelial cell growth and protease production, our results provide a basis for their therapeutic use as angiostatic molecules in cancer.",
keywords = "angiogenesis, angiogenesis inhibitors, human endothelial cells",
author = "Maier, {Jeanette A M} and Domenico Delia and Thorpe, {Philip E.} and Giampietro Gasparini",
year = "1997",
doi = "10.1097/00001813-199703000-00004",
language = "English",
volume = "8",
pages = "238--244",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11

AU - Maier, Jeanette A M

AU - Delia, Domenico

AU - Thorpe, Philip E.

AU - Gasparini, Giampietro

PY - 1997

Y1 - 1997

N2 - Angiogenesis plays a key role in tumor growth, progression and metastasis. The modulation of angiogenesis represents a potentially useful target for novel forms of anticancer therapy. Two such modulators are AGM-1470 (TNP-470, angioinhibin), which is a synthetic analog of the antibiotic fumagallin, and the monoclonal antibody TEC-11 to endoglin. We investigated the mechanisms of action of these modulators on human microvascular and macrovascular endothelial cells and on the transformed endothelial cell line ECV-304 in vitro. The administration of AGM-1470 or TEC-11 resulted in a significant inhibition of cell proliferation in all cell types used; this effect was reversible upon removal of these compounds from the culture medium. Furthermore, biochemical and morphological analyses showed that neither AGM-1470 or TEC-11 induce apoptosis. Both AGM-1470 and TEC-11 inhibited the production of urokinase-type plasminogen activator (u-PA), an enzyme involved in the early steps of neovascularization. Finally, the incubation of endothelial cells with both AGM-1470 and TEC-11 did not produce an additive effect on growth cell inhibition, apoptosis or u-PA production. Since both AGM-1470 and TEC-11 inhibit crucial events such as endothelial cell growth and protease production, our results provide a basis for their therapeutic use as angiostatic molecules in cancer.

AB - Angiogenesis plays a key role in tumor growth, progression and metastasis. The modulation of angiogenesis represents a potentially useful target for novel forms of anticancer therapy. Two such modulators are AGM-1470 (TNP-470, angioinhibin), which is a synthetic analog of the antibiotic fumagallin, and the monoclonal antibody TEC-11 to endoglin. We investigated the mechanisms of action of these modulators on human microvascular and macrovascular endothelial cells and on the transformed endothelial cell line ECV-304 in vitro. The administration of AGM-1470 or TEC-11 resulted in a significant inhibition of cell proliferation in all cell types used; this effect was reversible upon removal of these compounds from the culture medium. Furthermore, biochemical and morphological analyses showed that neither AGM-1470 or TEC-11 induce apoptosis. Both AGM-1470 and TEC-11 inhibited the production of urokinase-type plasminogen activator (u-PA), an enzyme involved in the early steps of neovascularization. Finally, the incubation of endothelial cells with both AGM-1470 and TEC-11 did not produce an additive effect on growth cell inhibition, apoptosis or u-PA production. Since both AGM-1470 and TEC-11 inhibit crucial events such as endothelial cell growth and protease production, our results provide a basis for their therapeutic use as angiostatic molecules in cancer.

KW - angiogenesis

KW - angiogenesis inhibitors

KW - human endothelial cells

UR - http://www.scopus.com/inward/record.url?scp=0030932552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030932552&partnerID=8YFLogxK

U2 - 10.1097/00001813-199703000-00004

DO - 10.1097/00001813-199703000-00004

M3 - Article

VL - 8

SP - 238

EP - 244

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 3

ER -